Banque Pictet & Cie SA Reduces Holdings in Astrazeneca PLC (AZN)
Banque Pictet & Cie SA decreased its holdings in Astrazeneca PLC (NYSE:AZN) by 0.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 267,899 shares of the company’s stock after selling 1,548 shares during the period. Banque Pictet & Cie SA’s holdings in Astrazeneca PLC were worth $17,810,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth $105,000. WFG Advisors LP grew its stake in shares of Astrazeneca PLC by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in shares of Astrazeneca PLC by 71.2% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after purchasing an additional 1,769 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of Astrazeneca PLC by 18.4% during the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after purchasing an additional 846 shares in the last quarter. Finally, Westport Asset Management Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth $170,000. Institutional investors and hedge funds own 14.16% of the company’s stock.
Astrazeneca PLC (NYSE:AZN) traded up $0.13 during mid-day trading on Friday, hitting $33.52. 1,991,200 shares of the stock traded hands, compared to its average volume of 4,816,348. The firm has a market capitalization of $83,360.00, a price-to-earnings ratio of 7.97, a PEG ratio of 3.15 and a beta of 0.79. Astrazeneca PLC has a twelve month low of $25.55 and a twelve month high of $35.60. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.32 earnings per share. sell-side analysts expect that Astrazeneca PLC will post 1.93 EPS for the current year.
Several equities analysts have issued reports on the stock. BMO Capital Markets set a $38.00 price objective on shares of Astrazeneca PLC and gave the company a “buy” rating in a research note on Wednesday. Leerink Swann upped their price objective on shares of Astrazeneca PLC from $31.00 to $34.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Citigroup Inc. upgraded shares of Astrazeneca PLC to a “buy” rating in a research note on Wednesday, October 18th. Cowen and Company restated a “hold” rating and issued a $37.00 price objective on shares of Astrazeneca PLC in a research note on Tuesday, October 17th. Finally, Credit Suisse Group raised shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.20.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.